Lung Cancer: Mechanisms of Lung Cancer |

Exploration of Genome-wide microRNA in Lung Adenocarcinoma With EGFR Exon 19 Deletion: miR-3196 as a Potential Biomarker FREE TO VIEW

Lixia Ju, PhD; Mingquan Han; Chao Zhao; Xuefei Li
Author and Funding Information

Shanghai Pulmonary Hospital, Shanghai, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A329. doi:10.1016/j.chest.2016.02.342
Text Size: A A A
Published online

SESSION TITLE: Mechanisms of Lung Cancer

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Saturday, April 16, 2016 at 02:15 PM - 03:45 PM

PURPOSE: The findings of EGFR mutations and the development of targeted therapies have significantly improved the overall survival of lung cancer patients. Still, the prognosis remains poor, so we need to know more about the genetic alterations in lung cancer. MicroRNAs are dysregulated in lung cancer, and microRNAs can regulate EGFR. So it is important to predict the candidate microRNAs that target mutated EGFR and to investigate the availability of these candidate microRNAs regulators in lung cancer.

METHODS: In this study, we investigated the difference of microRNAs expression in lung adenocarcinoma cell lines with EGFR exon 19 deletion (H1650 and PC9) and wild-type (H1299 and A549) using the Phalanx Human Whole Genome Microarray. Then the expression of individual microRNAs was validated by qRT-PCR assays. Moreover, we have detected microRNAs expression in serum of lung adenocarcinoma patients with EGFR exon 19 deletion and wide-type.

RESULTS: The expression of 1,732 microRNAs was evaluated, and we found that microRNAs expression was different between these two groups. Hsa-miR-141-3p, hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3182, hsa-miR-934 were up-regulated and hsa-miR-3196 was down-regulated in the EGFR exon 19 deletion group compared with wide-type group. The detection of circulating microRNAs showed that miR-3196 was down-regulated in lung adenocarcinoma patients with EGFR exon 19 deletion compared with wide-type.

CONCLUSIONS: It is suggested that microRNA associates with EGFR exon 19 deletion and miR-3196 can be further explored for potential predictor and targeted biomarker when it’s difficult to get the tumors.

CLINICAL IMPLICATIONS: It might spark the design of novel therapeutics to combat the development of resistance to EGFR-TKIs or develop new targeted therapy.

DISCLOSURE: The following authors have nothing to disclose: Lixia Ju, Mingquan Han, Chao Zhao, Xuefei Li

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543